{"id":35656,"date":"2025-08-11T17:02:41","date_gmt":"2025-08-11T17:02:41","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/gastric-cancer-market-on-growth-trajectory-novel-therapies-drive-momentum-through-2034-delveinsight\/"},"modified":"2025-08-11T17:02:41","modified_gmt":"2025-08-11T17:02:41","slug":"gastric-cancer-market-on-growth-trajectory-novel-therapies-drive-momentum-through-2034-delveinsight","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/gastric-cancer-market-on-growth-trajectory-novel-therapies-drive-momentum-through-2034-delveinsight\/","title":{"rendered":"Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\">New York, USA, Aug.  11, 2025  (GLOBE NEWSWIRE) &#8212; <b>Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight\u00a0<\/b><\/p>\n<p align=\"justify\"><b><i>The outlook for the gastric cancer treatment market appears favorable, fueled by progress in targeted therapies and immunotherapies. Traditionally, platinum-based chemotherapy has served as the primary treatment for early-stage gastric cancer, underscoring the demand for more effective alternatives.\u00a0<\/i><\/b><\/p>\n<p align=\"justify\">DelveInsight\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq3D8q1y3hqMAq9oq7Uc9YX9FPdeLdi3JzHCk1F0CyoVSR4Tjdg40jlxq0X0q1_V84Ksy9ttf9exHYMlosdNBSrQ8NMYuYG9azgPwcBjKAGBKhGzQfv2omEbKRgBysA2o7j2JW7XLXnm14U-_S_Z_IqVXtYdUmhOm65hiNBoeG-Bftj7QtM1YVfSSJHfwXjH87ML4EzxRJV_THYagFZKk2SqNwKsgi36aUxh6IYquZcFEgChkEgmZBglEmbClvuE\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastric Cancer Market Insights<\/b><\/a> report includes a comprehensive understanding of current treatment practices, emerging gastric cancer drugs, market share of individual therapies, and current and forecasted gastric cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/p>\n<p align=\"justify\"><b>Key Takeaways from the Gastric Cancer Market Report<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">According to      DelveInsight\u2019s analysis, the total gastric cancer market size is expected      to grow positively by 2034.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The United States      accounts for the largest market size of gastric cancer, in comparison to      EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The total number of      incident cases of gastric cancer (including GEJ) in the 7MM accounted for approximately      <b>211K<\/b> in 2024. These cases are expected to increase by 2034.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Prominent      companies, including <b>Amgen, Jazz Pharmaceuticals, BeiGene, Zymeworks,      AstraZeneca, ALX Oncology, Pfizer, KLUS Pharma, Enliven Therapeutics,      Ambrx, NovoCodex, <\/b>and others, are actively working on innovative      gastric cancer drugs.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Some of the key      gastric cancer therapies in the pipeline include <b>Bemarituzumab, ZIIHERA      (zanidatamab), Rilvegostomig, AZD0901, Evorpacept (ALX148), TUKYSA      (tucatinib), A166 (Trastuzumab botidotin), ELVN-002, ARX788<\/b>, and others. These      novel gastric cancer therapies are anticipated to enter the gastric cancer      market in the forecast period and are expected to change the market.<\/li>\n<\/ul>\n<p align=\"justify\">Discover which gastric cancer medications are expected to grab the market share @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq3D8q1y3hqMAq9oq7Uc9YX9FPdeLdi3JzHCk1F0CyqlQatnouJp-ilWjnhnlfFzlGHnJ19CL7bQR09Q00Sb8oVaNYZ-HDQWMOHk5B_MwnQ_CCmxkfe6FJHux3LdoSaD2s0GNh1WF-Jo9v0wF_tpyvy9ECbxvBOlAIlJkWwZpUr5p8uKToigkZwLjGsgvYPdd66ZE5gSyzlBWWcd7WSNR-uRv76vLrJ3XP-Ai8R7zs7I0ajEK4sS5gKwarkmE5U8\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastric Cancer Market Report<\/b><\/a><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq3D8q1y3hqMAq9oq7Uc9YX9FPdeLdi3JzHCk1F0CyoEz6oP2OYwA7e3QS6h9ALWmmjE0qNIWAucZzGwdnEQRuxpzwjgUR2-9-f-6IN4W3CD2aDohy861g7CxteUAz-QvyFiIr7OoQMkSvAll1GN5kigg5jPjohlNjKtgAoNhXONI48VeoYz3EP2uSneQ5WuLQUhnImp0FjJWcXaGhVIs6Ct_MenakXArP74zlIbnNFZ63qh8rwii3kyBK5Di2do\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastric Cancer Market Dynamics<\/b><\/a><\/p>\n<p align=\"justify\">The gastric cancer market dynamics are anticipated to change in the coming years. HER2-targeted therapies such as <b>HERCEPTIN, ENHERTU,<\/b> and the anti-PD1 therapy <b>KEYTRUDA <\/b>offer more precise treatment options that improve efficacy while minimizing side effects compared to traditional chemotherapy. ENHERTU, developed by <b>Daiichi Sankyo and AstraZeneca<\/b>, is expanding into the f<b>irst-line (1L) treatment setting<\/b>, which is expected to boost its patient share and drive market growth.\u00a0<\/p>\n<p align=\"justify\">Additionally, there is <b>growing research interest in combining next-generation HER2 inhibitors or bispecific antibodies<\/b> with immune checkpoint inhibitors (ICIs), presenting a significant opportunity to enhance treatment outcomes and improve patient survival. Overall, the gastric cancer market is poised for expansion, driven by <b>rising incidence rates, an aging population, and continued advancements<\/b> in treatment approaches, encouraging further investment in research and development.<\/p>\n<p align=\"justify\">Furthermore, many potential therapies are being investigated for the treatment of gastric cancer, and it is safe to predict that the treatment space will significantly impact the gastric cancer market during the forecast period. Moreover, the <b>anticipated introduction of emerging therapies<\/b> with improved efficacy and a further <b>improvement in the diagnosis rate<\/b> is expected to drive the growth of the gastric cancer market in the 7MM.<\/p>\n<p align=\"justify\">However, several factors may impede the growth of the gastric cancer market. HER2+ gastric cancer is an aggressive form of the disease with a <b>significantly high mortality rate and poor prognosis<\/b>, driven by low screening rates, a <b>high incidence of refractory or relapsed tumors<\/b>, and an older patient population; furthermore, the <b>complex tumor biology, including intratumoral heterogeneity<\/b>, poses challenges for effective treatment and <b>limits current therapies,<\/b> while the propensity for developing resistance to targeted treatments necessitates ongoing development of next-generation agents, thereby <b>increasing R&amp;D costs<\/b>.<\/p>\n<p align=\"justify\">Moreover, gastric cancer treatment poses a <b>significant economic burden<\/b> and disrupts patients\u2019 overall well-being and QOL. Furthermore, the gastric cancer market growth may be offset by <b>failures and discontinuation of emerging therapies<\/b>, <b>unaffordable pricing<\/b>, <b>market access and reimbursement issues<\/b>, and a <b>shortage of healthcare specialists<\/b>. In addition, the <b>undiagnosed, unreported cases and the unawareness<\/b> about the disease may also impact the gastric cancer market growth.<\/p>\n<p align=\"justify\"><\/p>\n<p align=\"justify\"><b>Gastric Cancer Treatment Market\u00a0<\/b><\/p>\n<p align=\"justify\">Gastrectomy is the mainstay of treatment for early-stage gastric or gastroesophageal junction (GEJ) cancers and can potentially cure patients; however, the survival rate for those with advanced resectable disease remains poor despite the advent of perioperative chemotherapy or adjuvant chemoradiation strategies. The choice of treatment depends on several factors, including tumor size, location, and the patient\u2019s overall health.\u00a0<\/p>\n<p align=\"justify\">In metastatic settings, HER2, a receptor overexpressed or amplified in 6\u201336% of gastric cancer patients, has emerged as a key therapeutic target. Targeted agents such as <b>HERCEPTIN <\/b>(trastuzumab), which inhibits HER2-mediated tumor proliferation, and immune checkpoint inhibitors like <b>KEYTRUDA <\/b>(pembrolizumab), which blocks PD-1\/PD-L1 interaction to enhance antitumor immune response, have received FDA approval. More recently, agents like <b>ENHERTU <\/b>(Daiichi Sankyo) and AIDIXI (Remegen Biosciences) have been approved for second- and third-line treatment, reflecting the growing role of precision therapies in managing advanced gastric cancer.<\/p>\n<p align=\"justify\">Learn more about the gastric cancer treatment options @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq3D8q1y3hqMAq9oq7Uc9frfYoHVHYpC7lNmxaqoXDJr90VHGChazp782gXA6aQCZb2O7vHjHbaX6U7X5YqzjWOmo3OzuKs4pcaJeZn0jF60sUgmjOLBvR9Y8sNLzJNDXp8-SUsTjRo97fLwrArHu8Y3u2bt0YPqurHuZp4nWwLNMzSBIZse5lQ8RFHIOzt6f_9IIZFv5jvHgX4HIOo9qi7rqdZKu_x8myO1khFL-MXrhR7zwsX4L7JwS2W24WomxVZNFqcYVHDBvrmeHnfDlg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastric Cancer Treatment Guidelines<\/b><\/a><\/p>\n<p align=\"justify\"><b>Gastric Cancer Emerging Drugs and Companies<\/b><\/p>\n<p align=\"justify\">Pharmaceutical companies developing therapies for treating gastric cancer include <b>Amgen <\/b>(Bemarituzumab), <b>ALX Oncology <\/b>(Evorpacept), <b>Jazz Pharmaceuticals, BeiGene, and Zymeworks <\/b>(ZIIHERA), <b>Enliven Therapeutics<\/b> (ELVN-002), <b>Ambrx and NovoCodex <\/b>(ARX788), <b>AstraZeneca <\/b>(Rilvegostomig and AZD0901), <b>KLUS Pharma<\/b> (A166), <b>Pfizer <\/b>(TUKYSA), and others with their candidates in different stages of clinical development.<\/p>\n<p align=\"justify\"><b>Bemarituzumab <\/b>is a monoclonal antibody targeting the fibroblast growth factor receptor 2b (FGFR2b) and is under investigation for the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. In April 2021, Amgen announced that the U.S. FDA had granted bemarituzumab breakthrough therapy designation. The drug is also undergoing Phase I and Phase II clinical trials in combination with other treatments for these cancers.<\/p>\n<p align=\"justify\">According to Amgen\u2019s May 2025 presentation, the company plans to release data from the Phase III FORTITUDE-101 trial, evaluating bemarituzumab as a first-line treatment for gastric cancer, in Q2 2025. Another Phase III trial, FORTITUDE-102, is expected to report results in the latter half of 2025.<\/p>\n<p align=\"justify\"><b>ZIIHERA<\/b>, a bispecific HER2-directed antibody that targets two external HER2 binding sites, received FDA accelerated approval in November 2024 for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), based on an FDA-approved diagnostic. The drug is currently in Phase III development for treating HER2-positive unresectable, locally advanced, or metastatic gastroesophageal adenocarcinoma.<\/p>\n<p align=\"justify\"><b>Zanidatamab<\/b>, being jointly developed by Jazz Pharmaceuticals and BeiGene under a license from Zymeworks, the original developer, is also progressing in the gastroesophageal adenocarcinoma (GEA) space. Jazz is exploring zanidatamab&#8217;s potential use in the neoadjuvant and adjuvant settings for GEA. The pivotal Phase III HERIZON-GEA-01 trial (NCT05152147), evaluating zanidatamab in combination with chemotherapy\u2014with or without tislelizumab\u2014as a first-line therapy for HER2-expressing metastatic GEA, is expected to deliver top-line data in Q2 2025.<\/p>\n<p align=\"justify\">As per a company presentation from January 2025, Jazz Pharmaceuticals anticipates submitting a supplemental Biologics License Application (sBLA) for zanidatamab later in 2025, aiming for approval in the first-line GEA setting.<\/p>\n<p align=\"justify\">The anticipated launch of these emerging gastric cancer therapies are poised to transform the gastric cancer market landscape in the coming years. As these cutting-edge gastric cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the gastric cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n<p align=\"justify\">To know more about new treatment for gastric cancer, visit @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq3D8q1y3hqMAq9oq7Uc9cVhK5o6bxBWizw-Nam2QiKhFavbfjkEUWMNLQhQRSO_uGd_zDizYfQT4GTEnkR9ruR6RRQiiycD6A0MOaltHMlFBPvPiiqgQsYCe0gGT3a0Rt5X3VMaeGwBLJY8U99ncOMuSQCrmUGBM4emqasOrwJtBuuVVpZ_IfjsMWdQsFV4Pok-4UO_CnLpquJUtFvqVgJvPBUvrxSuV76LuK58FHDGfApHKvWIIH5Xmbt2zYrE\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastric Cancer Management<\/b><\/a><b>\u00a0<\/b><\/p>\n<p align=\"justify\"><b>Recent Developments in the Gastric Cancer Market<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">In <b>February      2025, AstraZeneca<\/b> expects the first patient dosing of ENHERTU      (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or      metastatic gastric cancer or GEJ adenocarcinoma to begin in Q1 2025, with      data anticipated to be available after 2026.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>January 2025,      ALX Oncology<\/b> presented positive updated data from the ASPEN-06 Phase      II clinical trial at the 2025 ASCO Gastrointestinal Cancers Symposium,      demonstrating that the company&#8217;s investigational CD47-blocker, evorpacept,      produces a durable clinical response and exhibits a well-tolerated safety      profile in patients with previously treated HER2+ advanced gastric cancer      or GEJ cancer.<\/li>\n<\/ul>\n<p align=\"justify\"><b>Gastric Cancer Overview<\/b><\/p>\n<p align=\"justify\">Gastric cancer develops when malignant cells form in the stomach lining. The stomach wall consists of five layers: the mucosa, submucosa, muscularis propria, subserosa, and serosa. The tumour&#8217;s location and the depth of layer involvement are critical in determining the cancer\u2019s stage, which influences both treatment strategies and prognosis. As the cancer progresses from the mucosa to deeper layers, it becomes more advanced, requiring more intensive therapy.<\/p>\n<p align=\"justify\">To detect gastric cancer, physicians typically assess the patient&#8217;s medical and family history, conduct a physical examination, and carry out blood and stool tests to check for anemia or internal bleeding. Core diagnostic methods include an upper endoscopy with biopsy, using a thin, illuminated tube to inspect the esophagus, stomach, and duodenum, and barium swallow X-rays for imaging the digestive tract. Further staging is supported by advanced imaging techniques like CT scans, endoscopic ultrasound, PET-CT scans, and MRI, which help shape the treatment plan. The gastric cancer report outlines the disease\u2019s underlying biology, diagnostic methods, and a real-life patient case study that traces the journey from initial symptoms to diagnosis and complete treatment.<\/p>\n<p align=\"justify\"><b>Gastric Cancer Epidemiology Segmentation<\/b><\/p>\n<p align=\"justify\">The gastric cancer epidemiology section provides insights into the historical and current gastric cancer patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.<\/p>\n<p align=\"justify\">The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l5AkgmZk09yMJXp04sNcPeOd5HXuIBJx2l-k6jSGyXDowmE4-8I7hsatCeMhc8JSD7ZxzicFTlQ0zBi3ZVw9BlgPGxrLSX49w6njt20TSoCTTMQCIZomRtjZ_5g-JzS1wDLP5coXoK1zY5NcYvaKFMqBF-K_XRy5Da2aY6Qca8YZp_D9NlXw15B4dg55j6ChTr6KT4xMJebtmM7I4PxFaEgDWXf1ANvoo89Aeo2pJT88yg6H-ekZ7sRw0Omw0FdR\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>gastric cancer market report<\/b><\/a> proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM segmented into:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Total Incident      Cases of Gastric Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Stage-specific      Cases of Gastric Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Gender-specific      Cases of Gastric Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Biomarker-specific      Cases of Gastric Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Total Treatable      Cases of Gastric Cancer\u00a0<\/li>\n<\/ul>\n<p align=\"justify\">Download the report to understand which factors are driving gastric cancer epidemiology trends @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq3D8q1y3hqMAq9oq7Uc9frfYoHVHYpC7lNmxaqoXDIrZq_L2sP6dXvEu0DJ6UY0kBvl2O-ocShFUYRlb5FstZS6l12mDn31U63CnKIP8wm6dCtYWNBBqphvOYPhwBgB5stBgQ1Wg81WGF3wqwXtibBhXvGqTl4q21P9fHjHUcSutZ8IDgDUwSdMHdCo4xvMR4mZsJpRSsDrBct8AGqxYAVAz9aJR-Gzak6CXgdyj70AdkD9ZFCuRHxuE8nl8Lt9jmR5PgrdH0ZAMbQ2Sq6-UA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastric Cancer Treatment Algorithm<\/b><\/a><\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Gastric Cancer Report Metrics<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Details<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Study Period<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2020\u20132034<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Gastric Cancer   Report Coverage<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7MM [The   United States, the EU-4 (Germany, France, Italy, and Spain), the United   Kingdom, and Japan]<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Gastric Cancer Companies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Amgen, Jazz   Pharmaceuticals, BeiGene, Zymeworks, AstraZeneca, ALX Oncology, Pfizer, KLUS   Pharma, Enliven Therapeutics, Ambrx, NovoCodex, and others<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key   Gastric Cancer Therapies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Bemarituzumab,   ZIIHERA (zanidatamab), Rilvegostomig, AZD0901, Evorpacept (ALX148), TUKYSA   (tucatinib), A166 (Trastuzumab botidotin), ELVN-002, ARX788, KEYTRUDA,   ENHERTU, OPDIVO, CYRAMZA, and others<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b>Scope of the <\/b><b>Gastric Cancer<\/b><b> Market Report<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><b>Gastric Cancer      Therapeutic Assessment: <\/b>Gastric Cancer current      marketed and emerging therapies<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Gastric Cancer<\/b>      <b>Market      Dynamics:<\/b>      Conjoint Analysis of Emerging Gastric Cancer Drugs<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Competitive      Intelligence Analysis:<\/b> SWOT analysis and Market      entry strategies<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Unmet Needs, KOL\u2019s views, Analyst\u2019s      views, Gastric Cancer Market Access and Reimbursement<\/b><\/li>\n<\/ul>\n<p align=\"justify\">Discover more about gastric cancer drugs in development @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq3D8q1y3hqMAq9oq7Uc9fRB3xMFi3dRL9VZ1AF_ImAG20xO6gdPT7ivpyz7Lsf3J1SCW5QjLHtvf-uJ5F35dFw675DBkGDhr_tNF5Jgy_RWzKATqNLPj-k7yjNKgq2lFELU2yEn44EuONkcB9blbK6OPPZgAzoxMHMGeo2MpGaNQWZd_x19RROPa1yXFNe3HTV6Bxuf83yHUHeVVcpGGmE9hsa1a93uHRB7uRDAwM956oHamTcC822qETWH5OPS\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastric Cancer Clinical Trials<\/b><\/a><\/p>\n<p align=\"justify\"><b>Table of Contents<\/b><\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">1<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Insights<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Executive Summary<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Events<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Market Methodology<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Gastric Cancer: Market Overview at a Glance<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Share (%) Distribution of Gastric Cancer by   Therapies in 2020<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Share (%) Distribution of Gastric Cancer by   Therapies in 2034<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Disease Background and Overview: Gastric Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Risk Factors<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Symptoms<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Pathophysiology and disease pathways<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Diagnostic Tests: Biomarker assays<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment and Guidelines<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Current Treatment Landscape<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Patient Population<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Assumptions and Rationale<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Incident Cases of Gastric Cancer in the 7MM\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Incident Cases of Gastric Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Stage-specific Cases of Gastric Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Gender-specific Cases of Gastric Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Biomarker-specific Cases of Gastric Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Treatable Cases of Gastric Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">10<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Patient Journey<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Marketed Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Competitors<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">ENHERTU (Fam-Trastuzumab Deruxtecan-nxki): AstraZeneca\/Daiichi   Sankyo<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Product Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Regulatory Milestones<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Development Activities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Development<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.4.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Trial Information<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Safety and Efficacy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">OPDIVO (nivolumab): Bristol-Myers Squibb<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \"><i>List to be continued in the report\u2026<\/i><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Emerging Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Competitors<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Bemarituzumab: Amgen<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Product Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Developmental Activities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Development<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Trial Information<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Safety and Efficacy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and   Zymeworks<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \"><i>List to be continued in the report\u2026<\/i><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Gastric Cancer: Market Size<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Outlook<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Conjoint Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Market Forecast Assumptions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Cost Assumptions and Rebates<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Pricing Trends<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analogue Assessment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Launch Year and Therapy Uptakes<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Gastric Cancer in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.6.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Gastric Cancer in the United States\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.6.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Gastric Cancer by Therapies in the United   States\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Gastric Cancer in EU4 and the UK\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Gastric Cancer by Therapies in EU4 and the   UK\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.8.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Gastric Cancer in Japan\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.8.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Gastric Cancer by Therapies in Japan\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">14<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Unmet Needs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">15<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">SWOT Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">16<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">KOL Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Access and Reimbursement<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">18<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Bibliography<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">19<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Report Methodology<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b>Related Reports<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq3D8q1y3hqMAq9oq7Uc9Xv4RXje4HQQYNjQpgfJCleBgJrpsd-0GHnoyNxGzRD5N0ukgPGLD5Ctkf7dOILu-DMahs6EnwfZJnTzo1tqWF-6a-HjFPTrocUHt91Ysf3szkhO9eY7kIEoBES7LeNu9NUONo8G7Iq5V5aC7JJFKwvg5fY54Y3sK__qBaSG3Iek5obvl7K7lneexJiAtxk6W97BSqjs6jgKEl2j50Nt5iBkWMdNstl6rKYwsEKsi3c8\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastric Cancer Pipeline<\/b><\/a><\/p>\n<p align=\"justify\"><b>Gastric Cancer Pipeline Insight \u2013 2025<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gastric cancer companies, including<b> EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp &amp; Dohme, Hutchison Medipharma Limited, Genome &amp; Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech,\u00a0 CARsgen Therapeutics Co., Ltd., Zymeworks Inc.,\u00a0 NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc.,\u00a0 Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, <\/b>among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HNJyKSuvGheLCGigAWg7Cv-b9W34wcTJQEM1u6yLxErJQLcd60dtIev02nNaNUve0VgbrsdFMXWax7XfdbY2X1Rhz2FopKUA3pIVRqkMJV6FWpFfvyvSuGG_3bATLMG1uIciEsAoehHAZD2j60ZcKPF1QPcQMjgZt63mEgw--_GDrnclYxi8jbIIhX7UUkfVfD2LSpSxwiL87QM8KzJM-ycONL6jdKlnK_S5DS2zZfTOJYhxVSaAxNdCDXhRseZK3gphRSOmEwN1KX3lrqSJCw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>HER2+ Gastric Cancer Market\u00a0<\/b><\/a><\/p>\n<p align=\"justify\"><b>HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast \u2013 2034<\/b> report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HER2+ gastric cancer companies including <b>AstraZeneca, Daiichi Sankyo, Merck, Jazz Pharmaceuticals, BeiGene, Zymeworks, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, <\/b>among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HNJyKSuvGheLCGigAWg7Cv-b9W34wcTJQEM1u6yLxEoT7gBckpBLGj03CgaMHcvt435XvLUKRYNRVMiQiv6L6lU4KHtfEL-aMjDdi_LKG4FSuwCDB1wkUS4ywaknuls_dmoTVuNKQzi1HF1KCLSImtmlbuYeAiLIYHPYotC7oA2n1kgVwOfiz_GQpaIynYg6L_ae41X9Bs7m6PbsBAMurTVvpM8nDfBct4VoHTtyMthBRx_wfqfG5Y5-CyuqT1kiwhxc63EB1L9ed_qJPCe-VjUPb7byjTNiH_KmOQa58IE=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>HER2+ Gastric Cancer Pipeline<\/b><\/a><\/p>\n<p align=\"justify\"><b>HER2+ Gastric Cancer Pipeline Insight \u2013 2025<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2+ gastric cancer companies, including<b> Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, <\/b>among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r-G1yeq0Gjd-WIrnPk4a-m-xYoDhiWr_T8j3hSGi2MbvpjjCRjwPLyXTyNgHILyr7XHkqFfYWsGN77UMfgujg1_pYkP3HT-CgfopHKgl7ZIfXmskayT_Icm2csZVdPVyKRxrSrAndNp2TBbFvai0xIZSt52s2kls7FYLxam84CJjI-gqKWkVOfDe8GI8ePzQ49o3JN00hgYv6trITgdg1UP9IPlOP2lphcF3g1X8arOEu8lizm9ATWG4J4yIaYzanOK5gpFAlqvXX1Sav9MUcA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Metastatic Prostate Cancer Market\u00a0<\/b><\/a><\/p>\n<p align=\"justify\"><b>Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast \u2013 2034<\/b> report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including <b>AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis <\/b>among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HNJyKSuvGheLCGigAWg7Cv-b9W34wcTJQEM1u6yLxErHPkfubMFrJUIkoTd6ADO2iQNhKuTA20PUBJ-8Jt4Et4hEbOyKMKFGozcYjysCN59AQMlflYJ9o02XmQiPLHwNCPkYIS9tFR1kPiTA9bHAK6IqRH3s1ofEUDm_A_9v5z_Gu8uxXEMyfgge44bzXSFuroCUAoUq4-WjZGSQp9Z8oRik4PVu4zqsb99yXqZl2VIboiOefZovVTHiIJV7EmzmuiEAAE6IZPtf1usDG94Ri6hGzsrVwoTd4mWoLUd4WLc=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>HER2+ Gastric Cancer Epidemiology<\/b><\/a><\/p>\n<p align=\"justify\"><b>HER2+ Gastric Cancer<\/b><b> Epidemiology Forecast \u2013 2034<\/b> report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the HER2+ gastric cancer epidemiology trends.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oq3D8q1y3hqMAq9oq7Uc9YntLFJRtsfxijjJr0LYVlYCGlJtmX4iLZqfL_xzaE4J2p9vqZ3luoUQJbgOdv5We6iyGjCh8vMlt2W4gf5cKMvQ6wfFQdtb2Ld7nML1UITrDP7drexOOQmMRFPSAFruUeGYrS3IJ3AdKCNYkNMD8qa0Phsf2sCy2gOqGiDGFc1ezWLfJMT0DWL0_x6gQ6nHZf3aDHRxb_IEeCWb5_z13zgpwnqp_gikvfenKaFd3Yh8qj67LyLdIG34mIucodae8A==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastric Cancer Epidemiology<\/b><\/a><\/p>\n<p align=\"justify\"><b>Gastric Cancer<\/b><b> Epidemiology Forecast \u2013 2034<\/b> report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the gastric cancer epidemiology trends.<\/p>\n<p align=\"justify\"><b>DelveInsight\u2019s<\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9zkJ7-5d6t52e3MBrGS5-Tt9yzC8l_qsSBchqhbGRomTvNw1VSzCE3QjxVdhdz16yEuzN3fXNLbCkG96JPjVzYjGITTwectLdER7Qm30oHYgBAP94cASrcsIiAn7Fc30xNpszCmbDZAOEYCHHoYVseQmczqytyDB1nvlYdR3yEkg5NlGLIVCH86qoF8rYspF\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b> Pharma Competitive Intelligence Service<\/b><\/a><b>: <\/b>Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific\/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.<\/p>\n<p align=\"justify\"><b>Other Business Pharmaceutical Consulting Services<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cffBVT-uv9QQuyS2DlAlAd_okpWCGBUBT4-blNTcoB0M9mOJPbScH9Gdl-zss6UH7hBo4iuqDheRmM4PxcdW60M4sF3k4v4fawStovrJKJsCyVLkXD4pH66Pw9yKP5Wj1Ev4S0MP_7q9zSrYBsYf-qgpReA1I2IVqIu7sxx087w=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Healthcare Conference Coverage<\/b><\/a><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BzWMwfkDwSRHPaaRkR1tQRbPg5A_hXPR9cKN4KsO4XLYyPmm_U8GJmFjBWk5uyo-PLg4-uj9lKM4pKBxDMIOcbzXirJ9am7RbpdMpfhyTbzIX01Ye8bMq-cDmiDszXfZ6Z78-pjEiLV5ujHAINqdMutbp0D4Y2HOjqqpe03TmmU=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Pipeline Assessment<\/b><\/a><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cffBVT-uv9QQuyS2DlAlAW7RgZReSjeLLPDayw5sgMGwBvdDKhA3trDfP_yR7BIsU1V12vgQcXgvdmi5cbrzx0HZTpOJ0xCC59K3V8p6cEhfUh2jVkAKbzBJfAj0d_ljCuevSVzMLzLDkCC83lJ6IW7EUWmJeC2rhuqlfZmbfl4=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Healthcare Licensing Services<\/b><\/a><\/p>\n<p align=\"justify\">Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JpgLaHNHv-dM4PjywmqKrqqBgrQ3bBF40SLnA6IIbS_VNN7iJIYpkl6YvQl3QEHjScF1l0pkXdh2k48lO-a6H8UHiTeZiI6rv6TnmVd3cL-60D2jM2QiIVBuskvze-E4Q8DfWuD99IFytsduYtBUwg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Due Diligence Case Study<\/b><\/a><\/p>\n<p align=\"justify\"><b>About\u00a0DelveInsight<\/b><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<b>.<\/b><\/p>\n<p align=\"justify\"><b>Connect with us on<\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OWwCbF89qX84ahAJvSk0Z-YLp31No_rtAnDUeJSycfZcEzUQ9CU3sDB5YE1Afcqdp_JRPOyKBaWWmkUDIlg4tONu_LIT1_kpwKaYPoIIxyfPZCCRlJauJh9NiGYNHN6zVcl__GW7W7UJzjYwuTI-Bg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"> <b>LinkedIn<\/b><\/a><b>|<\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gsJxvg_ibqEMHdyGPJbPqF0OPbIzfrBBMNjAl9bNHTFl0AAS9nVWxMEyjOPeWSoNGIg0rFpxcMckbD_Q3iBAMVdl996skv-DQKPDmbmwoRo=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Facebook<\/b><\/a><b>|<\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n3QY3hQ-4AgIfX4F1TaWi28EoXkjPzL6Yztw16Y_celE2x7St7Ekn2R0CV1wC5g4Mhl-kZWcN46W08IfEkkmgoNuYDRTjpwHNO4FFj4UKcQ=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Twitter<\/b><\/a><\/p>\n<pre\/><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzYxZjc4MWUtODdkNS00NDg5LWI1NjgtMzlkNDBlMTg0NGUxLTEyMDQ5MzgtMjAyNS0wOC0xMS1lbg==\/tiny\/DelveInsight-Business-Research.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>New York, USA, Aug. 11, 2025 (GLOBE NEWSWIRE) &#8212; Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight\u00a0 The outlook for the gastric cancer treatment market appears favorable, fueled by progress in targeted therapies and immunotherapies. Traditionally, platinum-based chemotherapy has served as the primary treatment for early-stage gastric cancer, underscoring [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":35657,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/dbcddd65-71dd-4559-8875-ae89ac4f96db","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-35656","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/35656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/comments?post=35656"}],"version-history":[{"count":0,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/35656\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media\/35657"}],"wp:attachment":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media?parent=35656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/categories?post=35656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/tags?post=35656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}